Clinical Trials Browser

OTHER × poly ICLC × 1 year × Clear all

NCT02287428 2026-04-17

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1 Active not recruiting

Glioblastoma

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Phase 1 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Phase 1 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

8 enrolled 9 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06529822 2026-01-13

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1 Recruiting

Urinary Bladder Neoplasms

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT05010200 2026-01-07

PGV-Prostate

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT01970358 2025-12-29

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Phase 1 Completed

15 enrolled 8 charts

Melanoma

NCT06411691 2025-12-18

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Phase 1 Recruiting

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT04117087 2025-12-03

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Phase 1 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT05013216 2025-12-03

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT05111353 2025-11-05

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT05283109 2025-10-31

ETAPA I

Phase 1 Active not recruiting

Glioblastoma, Glioma

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Phase 1 Active not recruiting

Brain Neoplasms, Glioblastoma, Neoplasms

NCT04201873 2025-08-22

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Phase 1 Active not recruiting

Glioblastoma

NCT04116320 2025-07-14

AM-003

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma